Liver selective drug therapy
AssigneeHoward J. Smith & Associates Pty Ltd.
InventorHoward J. Smith
Life of this patent
Estimating the term…
Abstract
A method of pharmaceutical therapy comprising administering at least one pharmaceutical, complementary medicine, or herbal product, orally at a dose sufficient to provide a clinically effective blood level in the portal vein and less than that required to provide a clinically effective blood level in the peripheral circulation to thereby provide a dose-delivery rate having a selective clinical effect in the liver.
Claims27
A method of pharmaceutical therapy comprising administering at least one pharmaceutical orally at a dose-delivery rate sufficient to provide a clinically effective blood level in the portal vein and less than required to provide a clinically effective blood level in the peripheral circulation to thereby provide a dose-delivery rate having a selective clinical effect in the liver.
A method of treatment of a patient suffering from portal hypertension comprising administering orally to the patient a slow release formulation of at least one beta-blocker to provide a dose-delivery rate sufficient to provide beta-blockade in the liver and portal system and less than required to provide a blood level in the peripheral circulation that has an inhibitory effect on heart rate.
A method of treatment of a patient suffering from hypercholesterolemia comprising administering orally to the patient a slow-release formulation of at least one statin, wherein the dose-delivery rate is sufficient to provide a clinically effective blood level in the liver, but insufficient to produce an adverse systemic effect.
A method of treatment of a patient suffering from autoimmune hepatitis comprising administering to the patient at least one steroid effective in treating hepatitis wherein the at least one steroid is administered orally in a slow-release formulation providing a dose-delivery rate sufficient to provide effective steroid levels in the portal system and less than required to provide a systemic blood level to produce systemic effects.
A method of treatment of a patient suffering from hepatic hypoxia comprising orally administering to the patient at least one antioxidant in a slow-release formulation at a dose-delivery rate sufficient to provide an effective blood level in the portal system and less than that required to provide blood levels in the peripheral circulation sufficient to produce a clinical or adverse effect.
A method of treatment of a patient suffering from a form of liver disease other than portal hypertension, autoimmune hepatitis and hepatic hypoxia comprising administering to the patient a slow release formulation of drug sufficient to achieve effective blood levels in the liver and portal venous system and less than that required to produce a clinical or adverse effect elsewhere in the body.
A method of treatment of a patient suffering from a form of liver disease other than portal hypertension, hypercholesterolemia, hepatitis, viral hepatitis and hepatic hypoxia comprising administering to the patient a slow release of at least one complementary medicine or herbal product sufficient to achieve effective blood levels in the liver and portal venous system and less than that required to produce clinical or adverse effects elsewhere in the body.
Dependencies are inferred from the claim text.